Thousands to Trial Personalised Cancer Vaccines
Thousands of NHS cancer patients in England will access trials of personalised cancer vaccines at 30 hospitals through the Cancer Vaccine Launch Pad. The mRNA vaccines are designed to target and destroy remaining cancer cells, reducing recurrence risk. Elliot Pfebve, the first patient, received the treatment for bowel cancer at Birmingham's Queen Elizabeth Hospital.
Thousands of NHS cancer patients in England will have access to trials of personalised cancer vaccines at 30 participating hospitals via the Cancer Vaccine Launch Pad.
The vaccines, similar to mRNA Covid vaccines, aim to prime the immune system to target and destroy remaining cancer cells, reducing recurrence risk.
Elliot Pfebve, 55, is the first patient to receive this treatment for bowel cancer at Birmingham’s Queen Elizabeth Hospital.
Co-developed by BioNTech and Genentech, the vaccine was crafted using mutations specific to Pfebve’s cancer.
Dr. Victoria Kunene of Queen Elizabeth Hospital Birmingham expressed optimism toward the treatment becoming standard care.
The trial will involve over 200 participants from several countries and will complete by 2027.
Similar trials are underway for various cancers, with promising signs of fewer side effects compared to chemotherapy.
The vaccines, similar to mRNA Covid vaccines, aim to prime the immune system to target and destroy remaining cancer cells, reducing recurrence risk.
Elliot Pfebve, 55, is the first patient to receive this treatment for bowel cancer at Birmingham’s Queen Elizabeth Hospital.
Co-developed by BioNTech and Genentech, the vaccine was crafted using mutations specific to Pfebve’s cancer.
Dr. Victoria Kunene of Queen Elizabeth Hospital Birmingham expressed optimism toward the treatment becoming standard care.
The trial will involve over 200 participants from several countries and will complete by 2027.
Similar trials are underway for various cancers, with promising signs of fewer side effects compared to chemotherapy.
Translation:
Translated by AI
